Pfizer Could Year-End Target Hit on 2-to-1 Trial Payoff
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Begin retirement savings contributions as soon as you can. The earlier you start, the more time your money has to grow.
10,950 articlesPfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
As Zillow prepares for 2026 earnings season, investors crave clarity on growth, margins, and how the housing cycle co...
Bitcoin ETFs drew the most cash last week, with ETH and XRP also posting inflows. Here’s the latest breakdown on whic...
Great Elm's Q3 2026 earnings shed light on growth, margins, and capital allocation. This article breaks down the numb...
Looking for reliable income in 2026? This guide breaks down how to find the best high-yield dividend stocks, avoid di...
On a day shaped by geopolitical optimism, the stock market today showed modest gains as investors priced in the poten...
Salesforce is set to release Q1 results as investors look for evidence that its AI strategy can rekindle growth. A re...
A large fund sold a substantial stake in Kennametal, igniting questions about the stock's trajectory. This article br...
A veteran farmer-turned-businessman won Iowa’s GOP gubernatorial primary, challenging a Trump-backed candidate on pes...
Palantir emphasizes software-driven AI workflows with an asset-light model, while Oracle bets on cloud-scale GPU depl...
As workers start removing Trump’s name from the Kennedy Center, the nation’s capital watches a symbolic change that c...
What if chair kevin warsh just flipped the script on Fed communications? This analysis breaks down potential market r...